Cargando…

Soluble Human Epidermal Growth Factor Receptor 2 (sHER2) as a Potential Risk Assessment, Screening, and Diagnostic Biomarker of Lung Adenocarcinoma

Lung cancer is the leading cause of cancer-related death in the United States. Here, we evaluated the potential clinical utility of soluble human epidermal growth factor receptor 2 (sHER2) for the risk assessment, screening, and diagnosis of non-small cell lung cancer (NSCLC) using an unmatched case...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cosentino-Boehm, Abby L., Lafky, Jacqueline M., Greenwood, Tammy M., Kimbler, Kimberly D., Buenafe, Marites C., Wang, Yuxia, Branscum, Adam J., Yang, Ping, Maihle, Nita J., Baron, Andre T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4665577/ https://www.ncbi.nlm.nih.gov/pubmed/26835666 http://dx.doi.org/10.3390/diagnostics3010013

Ejemplares similares

Synergistic Targeting HER2 and EGFR with Bivalent Aptamer-siRNA Chimera Efficiently Inhibits HER2-Positive Tumor Growth
por: Xue, Lu, et al.
Publicado: (2018)

Anti-HER-2 therapy following severe trastuzumab-induced cardiac toxicity
por: Sadek, Ibrahim, et al.
Publicado: (2017)

In memory of the well-renowned Chinese cellular biologist Shien Sher-Pu
por: Shen, Nan, et al.
Publicado: (2022)

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
por: Perrier, Alexandre, et al.
Publicado: (2020)

SHER: A Colored Petri Net Based Random Mobility Model for Wireless Communications
por: Khan, Naeem Akhtar, et al.
Publicado: (2015)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2(+) Breast Cancer
por: Yu, Xiaolin, et al.
Publicado: (2017)

Indications and Complications of Hepatic Resection Patients at Sher-I-Kashmir Institute of Medical Sciences: An Observational Study
por: Kar, Irfan, et al.
Publicado: (2021)

Systemic toxicities of trastuzumab‐emtansine predict tumor response in HER2+ metastatic breast cancer
por: Tang, Shou‐Ching, et al.
Publicado: (2021)

Transient anabolic effects accompany epidermal growth factor receptor signal activation in articular cartilage in vivo
por: Shepard, John B, et al.
Publicado: (2013)

Expression of EGFR isoform D is regulated by HER receptor activators in breast cancer cells
por: Negrón-Vega, Lisandra, et al.
Publicado: (2022)

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies
por: Florido, Roberta, et al.
Publicado: (2017)

Morphological and molecular characterization of Hoplolaimus pararobustus (Schuurmans Stekhoven and Teunissen, 1938) Sher 1963 with its first report on Zea mays roots in Namibia
por: Marais, Mariette, et al.
Publicado: (2021)

Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
por: Laidi, Fatna, et al.
Publicado: (2014)

The Levels of Bone Alkaline Phosphatase (BALP) and Soluble Epidermal Growth Factor Receptor-2 (ECD/HER-2) in Pediatric Patients with Osteosarcoma During Clinical Treatment
por: Rychłowska-Pruszyńska, Magdalena, et al.
Publicado: (2018)

Human epidermal growth factor receptor 2 (HER2) and the future of bladder carcinoma
por: Sarkis, Julien, et al.
Publicado: (2020)

Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics
por: Wilken, Jason A, et al.
Publicado: (2010)

Human Epidermal Growth Factor Receptor 2 (HER-2/neu)-Directed Therapy for Rare Metastatic Epithelial Tumors with HER-2 Amplification
por: Shin, Daniel Sanghoon, et al.
Publicado: (2016)

Changes in the detection of human epidermal growth factor receptor 2 gene (Her-2) status for Her-2 fluorescent in situ hybridization testing
por: Xu, Ying, et al.
Publicado: (2022)

Soluble HER-2 in Patients with Head and Neck Squamous Cell Carcinoma
por: Khademi, Bijan, et al.
Publicado: (2013)

Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications
por: Iqbal, Nida, et al.
Publicado: (2014)

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer
por: Siena, S, et al.
Publicado: (2018)

EGFR isoforms and gene regulation in human endometrial cancer cells
por: Albitar, Lina, et al.
Publicado: (2010)

Incidence, histopathology, and surgical outcome of tumors of spinal cord, nerve roots, meninges, and vertebral column - Data based on single institutional (Sher-i-Kashmir Institute of Medical Sciences) experience
por: Bhat, Abdul Rashid, et al.
Publicado: (2016)

Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies
por: Schrohl, Anne-Sofie, et al.
Publicado: (2011)

Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
por: Vicario, Rocio, et al.
Publicado: (2015)

Impact of the Updated Guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2020)

An overview of resistance to Human epidermal growth factor receptor 2 (Her2) targeted therapies in breast cancer
por: Elshazly, Ahmed M., et al.
Publicado: (2022)

Detecting Human Epidermal Growth Factor Receptor 2 (HER2) Amplification: Proof of Concept of an Alternative Approach
por: Mudgal, Shikha, et al.
Publicado: (2023)

AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014)

Targeting Epidermal Growth Factor Receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (HER2) Expressing Bladder Cancer Using Combination Photoimmunotherapy (PIT)
por: Siddiqui, Mohammad R., et al.
Publicado: (2019)

Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer
por: Choi, Jin Hyuk, et al.
Publicado: (2020)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer
por: Chan, David S. Y., et al.
Publicado: (2012)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer
por: McGranahan, Tresa M., et al.
Publicado: (2022)

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients
por: Asgeirsson, Kristjan S, et al.
Publicado: (2007)

The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer
por: Aznab, Mozaffar, et al.
Publicado: (2019)

Everyday Problem Solving and Instrumental Activities of Daily Living: Support for Domain Specificity
por: Kimbler, Kristopher J.
Publicado: (2013)

Analysis of clinicopathological characteristics and prognostic factors of early‐stage human epidermal growth factor receptor 2 (HER2)‐low breast cancer: Compared with HER2‐0 breast cancer
por: Wu, Qian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_euv82devoo2dbs7q7ngt4c3hnl